Delivering mitochondrial health
On June 29-30, Abliva will participate at Bioblast 2022: Inaugural Conference of Bioenergetics Communications in Innsbruck, Austria. Abliva's Communications Officer & Lab Manager, Eleonor Åsander Frostner, will present a summary of the company's recent preprint publication "Towards a treatment for mitochondrial disease: current compounds in clinical development".
Abliva will be attending Aktiespararna's Digital Temadag - Life Science, on Aug 31, 2022. CEO Ellen Donnelly will present the company at 6:20 p.m. CEST. Follow link below for further information.
In September, Abliva will attend mitoNice, an international congress dedicated to Mitochondrial Medicine.
More info to come.
On September 26 (Monday), 2022, Abliva will attend Aktiespararna's Aktiedagen Lund, at Elite Hotel Ideon. CEO Ellen Donnelly will present the company at 4 p.m. CEST. See below for more info and registration.
Abliva will attend the Nordic Life Science Days in Malmö, Sweden, on September 28-29, 2022. CEO Ellen Donnelly will be presenting the company at 11:00 CEST on Sep 29.
In October, Abliva will attend the Italian patient organization Mitocon's annual Mitochondrial Diseases Conference in Rome, Italy. On October 8, Abliva's Chief Medical Officer Magnus Hansson will give the talk: An adaptive, clinical Phase 2/3 study evaluating the efficacy of KL1333 in adult primary mitochondrial disease patients in Session 5: Challenges and pitfalls in clinical […]
Abliva will visit Aktiespararna Västra Blekinge/Bromölla in Olofström on November 8, 2022. Abliva's CFO Catharina Johansson and Communications Officer Eleonor Åsander Frostner will be presenting the company during the evening. See below for more info and registration.
Abliva will come to Aktiespararna's local club Sydöstra Skåne, in Tommarp, Sweden, on November 17, 2022. Abliva’s CFO Catharina Johansson and Communications Officer Eleonor Åsander Frostner will be presenting the company during the evening. See below for more info and registration.
In late November, Abliva will attend the annual scientific conference Mitochondrial Medicine - Therapeutic Development in Hinxton, UK. Abliva's Chief Medical Officer, Magnus Hansson, will present a poster on one of the important preparatory studies for the upcoming, potentially registrational, Phase 2 study, FALCON, with KL1333 in patients with mitochondrial diseases.
In late November, Abliva will attend Aktiespararna's Stora Aktiedagen Stockholm. The company's CEO, Ellen Donnelly, will present the company via Zoom on November 29, 2022, at 7:30 p.m. CET. See below for detailed information and a link to the event.
In December 2022, Abliva will attend the 7th Annual Nordic American Life Science Conference, hosted by DNB, Nasdaq, and Business Sweden, in New York, US. Abliva's CEO Ellen Donnelly will present the company on December 8.
